Technical Analysis for OMER - Omeros Corporation

Grade Last Price % Change Price Change
grade B 12.24 0.25% 0.03
OMER closed up 0.25 percent on Friday, April 3, 2020, on 55 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical OMER trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Fell Below 20 DMA Bearish 0.25%
Wide Bands Range Expansion 0.25%
Fell Below 50 DMA Bearish -5.48%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.48%
20 DMA Support Bullish -5.48%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. The company derives product candidates from its proprietary PharmacoSurgery platform that is designed to enhance clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological, and other surgical and medical procedures. The company's product candidates include OMS302, which has completed two Phase III clinical trials for use during intraocular lens replacement surgery, including cataract and other lens replacement surgery; OMS103HP that is in Phase III program for use during arthroscopic procedures comprising partial meniscectomy surgery; and OMS201, which has completed Phase I/Phase II studies for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. Its clinical programs also consist of OMS824, which is in Phase I clinical trial for the treatment of cognitive disorders, including schizophrenia; and OMS405 that is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse. The company's preclinical product development programs comprise OMS721 for hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, wet age-related macular degeneration, ischemia-reperfusion injury, and transplant-related complications; OMS527 for addictions and compulsive disorders, and movement disorders; and OMS616 for surgical and traumatic bleeding. In addition, it is developing G protein-coupled receptors (GPCR) programs for multiple disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Medicine Health Biopharmaceutical Medical Specialties Surgery Inflammation Clinical Trial Disorders Schizophrenia Ophthalmology Clinical Research Wet Age Related Macular Degeneration Movement Disorders Urology Cataract Cognitive Disorders Paroxysmal Nocturnal Hemoglobinuria Surgical Specialties Arthroscopy Hemolytic Uremic Syndrome

Is OMER a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.92
52 Week Low 8.5
Average Volume 905,227
200-Day Moving Average 15.04
50-Day Moving Average 13.14
20-Day Moving Average 12.08
10-Day Moving Average 11.72
Average True Range 1.44
ADX 15.24
+DI 26.71
-DI 22.86
Chandelier Exit (Long, 3 ATRs ) 16.27
Chandelier Exit (Short, 3 ATRs ) 12.83
Upper Bollinger Band 16.03
Lower Bollinger Band 8.13
Percent B (%b) 0.52
BandWidth 65.45
MACD Line -0.41
MACD Signal Line -0.58
MACD Histogram 0.1687
Fundamentals Value
Market Cap 548.39 Million
Num Shares 44.8 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -8.33
Price-to-Sales 11.55
Price-to-Book 0.00
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.23
Resistance 3 (R3) 13.29 13.02 13.07
Resistance 2 (R2) 13.02 12.77 12.99 13.01
Resistance 1 (R1) 12.63 12.61 12.83 12.57 12.95
Pivot Point 12.36 12.36 12.46 12.33 12.36
Support 1 (S1) 11.97 12.11 12.17 11.91 11.53
Support 2 (S2) 11.70 11.95 11.67 11.47
Support 3 (S3) 11.31 11.70 11.42
Support 4 (S4) 11.25